Alexis Borisy


Alexis’ first job was selling peanuts at Wisconsin Badger football games at age 14.

Alexis Borisy is chairman of Relay Therapeutics’ board of directors, having been the founding investor and CEO of the company. He is a leading biotechnology entrepreneur and investor with more than 25 years of experience building, operating and investing in innovative science-based companies to make a positive difference in the world. Alexis is currently founder and executive chairman of EQRx, a new pharma company committed to making innovative medicines at dramatically lower prices for the benefit of people and society. Alexis is also a founder and operating chairman at Curie.Bio, and a co-founder of IDRx, a biopharmaceutical company transforming cancer treatment with purpose-built precision combination therapies.

Alexis co-founded Foundation Medicine, served as its first CEO, and then chairman, remaining on the board until the $5B acquisition by Roche. He also co-founded Blueprint Medicines (BPMC), served as interim CEO and continues to serve on the board. Additionally, he was a founding investor and is chairman of Tango Therapeutics. As a partner at Third Rock Ventures for a decade, Alexis was also a founding investor for Editas, REVOLUTION Medicines, Magenta Therapeutics, Celsius Therapeutics, and an investor in insitro and Thrive Early Detection, among others.

He founded his first company, CombinatoRx, when he was in his 20s, served as its CEO and brought the company public on the NASDAQ. He has been personally involved in tens of billions of dollars in financing and business development deals and has authored numerous scientific papers and patents. 

Alexis is currently chairman of the board of trustees of the Boston Museum of Science, and has served on the board of BIO and as the chairman of the National Venture Capital Association.

Graduate trained in chemistry and chemical biology at Harvard where he was a Howard Hughes predoctoral fellow, Alexis was honored as the Massachusetts Institute of Technology’s Technology Review Innovator of the Year. He was also chosen as the New England Entrepreneur of the Year in Life Sciences, was honored as a presidential scholar, and holds an undergraduate degree in chemistry from the University of Chicago.